The study concludes that increasing the dose of UPA offers no additional benefit, reinforcing that the standard 30 mg should ...
Complete Title: A Multi-phase, Dose-Escalation followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback